HALO logo
halo search icon
CUV
Clinuvel Pharmaceuticals Limited

CUV · Clinuvel Pharmaceuticals Limited

10.20

AUD
0.25 (2.51%)
24/06/2026 04:10:09 PM
+1
Price change (7D)

Unlock stock Insights

Create a free account to unlock price targets, recommendations, and commentary.

Overview

Market Cap

AU$514.36M

PE

14.40

EV/EBITDA

7

DIV Yield

0.5%

Franking

100%

MQV Rating

2Strong

As at 24/06/2026 04:10:09 PM

Price Chart

Description

Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.

  • All-Companies
  • All-Consensus
  • Consensus Cheap
  • Engulfing Bullish
  • Engulfing Bullish (Realtime)
  • Fakey Shakey - Short
  • Fakey Shakey - Short (Realtime)
  • GROWTH AUS
  • HALO Balance Sheet
  • HALO Ords
  • HALO Price Momentum
  • Recent Earnings downgrade

Key Fundamentals

EPS 3 yr Growth

70.90%

EBITDA Margin

44.70%

Operating Cashflow

$41m

Free Cash Flow Return

18.50%

ROIC

16.30%

Interest Coverage

NaN

Quick Ratio

9.30

Performance

52 weeks range

Low 8.35 - 14

Trade Value (12mth)

AU$313,620.00

1 week

6.42%

1 month

12.18%

YTD

-21.72%

1 year

-4.05%

All time high

45.88

Additional Data

Shares Outstanding (Fully Diluted)

51m

HALO Sector

Healthcare

Next Company Report Date

01-Sep-26

Next Ex Dividend Date

04-Sep-25

Next Dividend Pay Date

19-Sep-25

Reporting Currency

AUD

Short Sell (% of issue)

9.36

Consensus

Lock Icon

Unlock full consensus

Consensus score

Lock Icon/10

Recommendation

Buy

Target price

Lock Icon

Deviation

Lock Icon

Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Very Strong

Halo Model

Mqv

Strong

Garp

Neutral

Mqv Small

Neutral

Momentum

Price

Very Strong

Earnings

Weak

Growth

Earnings

Weak

Dividends

Strong

Quality

Capital Efficiency

Strong

Balance Sheet

Very Strong

Valuation

Lock Icon

Unlock full dataset

Value

Lock Icon

Consensus

Lock Icon

Yield

Lock Icon

News & Announcements

DateEvent
16 June 26ASXD
02 June 26ASXD
07 May 26ASXD
28 April 26ASXD
27 April 26ASXD

See beyond the curve.

One solution for research, investing and portfolio management.
Start FREE Trial
Want to learn more?Frequently asked questions.
1
What is the current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX)?
Halo FAQ
The current share price of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AUD$10.20.
2
What is the 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)?
Halo FAQ
The 52-week high share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AUD$14.00.
3
What is the 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX)?
Halo FAQ
The 52-week low share price for Clinuvel Pharmaceuticals Limited (CUV:ASX) is AUD$8.35.
4
What is the dividend yield for Clinuvel Pharmaceuticals Limited (CUV:ASX)?
Halo FAQ
The current TTM dividend payout for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 0.50.
5
What was Clinuvel Pharmaceuticals Limited (CUV:ASX) last dividend payment?
Halo FAQ
The last dividend payment of Clinuvel Pharmaceuticals Limited (CUV:ASX) is AUD$0.05.
6
What is the franking level for Clinuvel Pharmaceuticals Limited (CUV:ASX)?
Halo FAQ
Clinuvel Pharmaceuticals Limited (CUV:ASX) has a franking level of 100.00%.
7
In which sector is Clinuvel Pharmaceuticals Limited (CUV:ASX) classified?
Halo FAQ
Clinuvel Pharmaceuticals Limited (CUV:ASX) is classified in the Healthcare.
8
What is the price-to-earnings (P/E) ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX)?
Halo FAQ
The current P/E ratio for Clinuvel Pharmaceuticals Limited (CUV:ASX) is 14.40.